Optimisation du traitement médicamenteux des patients atteints de BPCO en état stable. Position de la Société de pneumologie de langue française. Actualisation 2021

Zysman, M.; Baptista, Bruno Ribeiro; Soumagne, Thibaud; Silva, Vanessa Marques da; Martin, Clémence; Menonville, C. Thibault De; Boyer, Laurent; Degano, Bruno; Panzini, Capucine Morélot; Burgel, P.-R.; Pérez, Thierry; Bourdin, Arnaud; Pégliasco, Hervé; Piperno, D.; Zanetti, Camila Bruna; Morel, H.; Delclaux, B; Delafosse, Christian; Lorenzo, Alain; Housset, B.; Chabot, F.; Devillier, Philippe; Deslée, G.; Roche, Nicolás

doi:10.1016/j.rmr.2021.02.070

Cited by 15 publications

(4 citation statements)

References 108 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The CASA-Q is a questionnaire validated in French which aims to rate cough and sputum and their respective impacts on quality of life. According to the national [ 24 ] and international [ 23 ] recommendations in force, the prescription of azithromycin is conditioned upon the specialist’s free, subjective appreciation of respiratory symptoms, including cough and sputum, in patients with COPD and frequent exacerbations. These symptoms will be assessed here by the CASA-Q [ 27 , 28 , 29 , 30 ].…”

Section: Methodsmentioning

confidence: 99%

“…Moreover, it also proved efficient in improving the cough-specific health status of patients with COPD [ 21 ] and the Leicester Cough Questionnaire (LCQ) scores of patients with resistant cough [ 22 ]. As a result, azithromycin is now proposed in international and French guidelines as a therapeutic tool for the prevention of exacerbations, in addition to optimal standard management [ 23 , 24 ]. However, the pathophysiological link between azithromycin administration and the reduction of COPD exacerbations has not been established.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Sputum-Rheology-Based Strategy for Guiding Azithromycin Prescription in COPD Patients with Frequent Exacerbations: A Randomized, Controlled Study (“COPD CARhE”)

et al. 2023

View full text Add to dashboard Cite

(1) Background: We have previously shown that sputum rheology can discriminate between patients with COPD and other muco-obstructive lung diseases, and that it is correlated with mucin content and sputum eosinophilia. We now hypothesize that it could be a more-accurate guide than clinical evaluation for the prescription of azithromycin to prevent exacerbations of COPD and to reduce exposure to antibiotics; (2) Methods: “COPD CaRhe” is a multicentric, randomized, controlled trial comparing outcomes in two parallel arms (36 vs. 36 patients). Patients will be recruited in the university hospitals of Montpellier, Bordeaux, and Toulouse, in France, and they should have a diagnosis of COPD with frequent exacerbations (≥3/year). Enrollment will occur during a routine visit to a respiratory department, and follow-up visits will occur every 3 months for a period of 1 year. At each visit, a 3-month prescription of azithromycin will be provided to those patients who obtain a score of <70 on the Cough and Sputum Assessment Questionnaire (CASA-Q) or a critical stress score of σc > 39 on a rheological assessment of sputum, depending upon their randomization group. The primary outcome will be the number of exacerbations of COPD; (3) Discussion: By using sputum rheology, the COPD CaRhe study may provide clinicians with an objective biomarker to guide the prescription of azithromycin while reducing the cumulative exposure to macrolides.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Sputum-Rheology-Based Strategy for Guiding Azithromycin Prescription in COPD Patients with Frequent Exacerbations: A Randomized, Controlled Study (“COPD CARhE”)

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Les recommandations présentées dans ce texte sont restreintes à l'atteinte pulmonaire du DAAT et leur nombre est volontairement limité. Elles sont complémentaires des recommandations nationales connexes, comme celles de la SPLF sur la BPCO [21][22][23] ou celles de l'Association Française pour l'Étude du Foie (AFEF) [24]. La méthodologie des recommandations a été approuvée par le conseil scientifique de la SPLF le 17 mai 2018.…”

Section: éTapes D'établissement Des Recommandationsunclassified

“…En dehors du traitement substitutif, le traitement de l'emphysème associé au DAAT est celui de toute BPCO : il associe donc une prise en charge pharmacologique et non pharmacologique. La SPLF a émis des recommandations pour la prise en charge de la BPCO [21,22], y compris les épisodes d'exacerbation [23]. Il n'y a pas lieu de répéter ces recommandations dans le présent document, où il suffira de rappeler quelques aspects particuliers, et la rareté d'études spécifiques au DAAT [222,223].…”

Section: Prise En Charge De La Bronchopneumopathie Chronique Obstruct...unclassified

Atteinte pulmonaire du déficit en alpha-1 antitrypsine. Recommandations pratiques pour le diagnostic et la prise en charge

Mornex

Balduyck

Bouchecareilh

et al. 2022

Revue des Maladies Respiratoires

View full text Add to dashboard Cite

Bronchopneumopathie chronique obstructive

Artaud-Macari,

Bonnaire,

Roger

et al. 2023

Gériatrie

View full text Add to dashboard Cite

Optimisation du traitement médicamenteux des patients atteints de BPCO en état stable. Position de la Société de pneumologie de langue française. Actualisation 2021

Cited by 15 publications

References 108 publications

Sputum-Rheology-Based Strategy for Guiding Azithromycin Prescription in COPD Patients with Frequent Exacerbations: A Randomized, Controlled Study (“COPD CARhE”)

Sputum-Rheology-Based Strategy for Guiding Azithromycin Prescription in COPD Patients with Frequent Exacerbations: A Randomized, Controlled Study (“COPD CARhE”)

Atteinte pulmonaire du déficit en alpha-1 antitrypsine. Recommandations pratiques pour le diagnostic et la prise en charge

Bronchopneumopathie chronique obstructive

Contact Info

Product

Resources

About